Glasziou P P
Department of Social and Preventive Medicine, University of Queensland, Brisbane.
Med J Aust. 1995 Jan 2;162(1):33-6.
I propose a new authority category for the Pharmaceutical Benefits Scheme (PBS)--authority to prescribe only within a controlled trial. This would benefit both the PBS and the pharmaceutical companies, but the main winners would be the Australian population, who would obtain better value for money spent by the PBS. Drugs which show promise, but for which conclusive evidence of advantage over standard therapy is lacking, or drugs for new indications, could be prescribed within a randomised trial. PBS support would fund a substantial portion of the trial costs. This proposal would greatly boost local and international investment in Australian medical research.
我提议为药品福利计划(PBS)设立一个新的审批类别——仅在对照试验范围内开出处方的审批权。这将对PBS和制药公司都有利,但主要受益者将是澳大利亚民众,他们将从PBS所支出的费用中获得更高的性价比。那些显示出前景,但缺乏优于标准疗法的确凿证据的药物,或者用于新适应症的药物,可以在随机试验范围内开出处方。PBS的支持将为试验成本的很大一部分提供资金。这一提议将极大地促进澳大利亚医学研究的国内外投资。